Abivax SA Sponsored ADR
(NASDAQ: ABVX)

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

113.980 -

-4.910 (-4.13%)
Range 112.880 - 119.160   (5.56%)
Open 118.730
Previous Close 118.890
Bid Price -
Bid Volume -
Ask Price -
Ask Volume -
Volume 1,031,120
Value 82,277,469
Remark -
Delayed prices. Updated at 29 Jan 2026 09:15.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis